ReviewNature reviews. Cardiology2014
Top 10 cardiovascular therapies and interventions for the next decade.
Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Low-dimensional materials for intracellular electrophysiology: advances from synthesis to applications.Microsystems & nanoengineering · 2026Review
- Maternal high-fat diet exacerbates atherosclerosis development in offspring through epigenetic memory.Nature cardiovascular research · 2025Article
- Transnational inequities in cardiovascular diseases from 1990 to 2019: exploration based on the global burden of disease study 2019.Frontiers in public health · 2024Article
- Improving vasculoprotective effects of MSCs in coronary microvessels - benefits of 3D culture, sub-populations and heparin.Frontiers in immunology · 2023Article
- A historical review of experimental imaging of the beating heart coronary microcirculation in vivo.Journal of anatomy · 2023Review
- Integrated Au-Nanoroded Biosensing and Regulating Platform for Photothermal Therapy of Bradyarrhythmia.Research (Washington, D.C.) · 2022Article
- Endothelial progenitor cells as the target for cardiovascular disease prediction, personalized prevention, and treatments: progressing beyond the state-of-the-art.The EPMA journal · 2020Review
- CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions.Scientific reports · 2019Article
- Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.EBioMedicine · 2019Article
- Myocardial death and dysfunction after ischemia-reperfusion injury require CaMKIIδ oxidation.Scientific reports · 2019Article
- Na/K-ATPase Signaling and Cardiac Pre/Postconditioning with Cardiotonic Steroids.International journal of molecular sciences · 2018Review
- Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction.Journal of cardiovascular translational research · 2018Article
- Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute.Cardiovascular drugs and therapy · 2018Article
- The RISK pathway and beyond.Basic research in cardiology · 2018Review
- Article
- Identification of Angiogenesis Rich-Viable Myocardium using RGD Dimer based SPECT after Myocardial Infarction.Scientific reports · 2016Article
- p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive Mice.Scientific reports · 2016Article
- Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development.Applied in vitro toxicology · 2016Review
- Can the DNA damage response be harnessed to modulate atherosclerotic plaque phenotype?Circulation research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) has become the most-common cause of death worldwide. The Western lifestyle does not promote healthy living, and the consequences are most devastating when social inequalities are combined with economic factors and population growth. The expansion of poor nutritional habits, obesity, and associated conditions (such as diabetes mellitus, hypertension, physical inactivity, and advancing age) are major risk factors for developing CVD and are increasing in prevalence. Individuals in low-income and middle-income countries are undergoing a major shift in cardiovascular risk factors as they adopt Western lifestyles, a phenomenon that is hastened by industrialization, urbanization, and globalization. In this Perspectives article, I predict the 10 most-promising advances in cardiovascular therapies and interventions. Our improved understanding of CVD might help us, during the next decade, to achieve a transition from treating complex disease to promoting global cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.